title: Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
abstract: BACKGROUND
  Cisplatin in combination with vinorelbine has reported an optimal activity/tolerance ratio when used in combination with radiotherapy in locally advanced unresectable non-small cell lung cancer. The currently available oral formulation of vinorelbine should be easier to use assuming a similar activity profile. An international phase II trial with vinorelbine oral and cisplatin as induction followed by oral vinorelbine and cisplatin with concomitant radiotherapy was implemented to evaluate the efficacy in terms of objective response (OR) following this combination as primary end point and duration or response, progression-free survival, overall survival, and safety as secondary endpoints.
  
  
  METHODS
  The study included patients between 18 and 75 years, with histologically proven untreated locally advanced inoperable stage IIIA/IIIB (supraclavicular lymph nodes and pleural effusion excluded) non-small cell lung cancer, adequate bone marrow, hepatic and renal function, Karnofsky performance status >/=80%. Patients were treated with oral vinorelbine 60 mg/m day 1,8 cycle 1 and 80 mg/m day 1,8 cycle 2 (if no grade 3-4 toxicity) and cisplatin 80 mg/m day 1 every 3 weeks for 2 cycles as induction. Patients without progression received oral vinorelbine 40 mg/m day 1, 8 and cisplatin 80 mg/m day 1 every 3 weeks for 2 more cycles with radiotherapy 66 Gy in 6.5 weeks.
  
  
  RESULTS
  Patient and disease characteristics (n = 54) included: median age 57 years; female sex 24%; stage IIIA 48% and IIIB 52%; Squamous carcinoma 59%, Karnofsky performance status 100% (range, 80-100%) 50%, patients >/=5% weight loss at baseline 7%. Relative dose intensities of oral vinorelbine/cisplatin were 86%/93% and 97%/98% at induction and in combination with radiotherapy, respectively. Forty-one patients (76%) increased oral vinorelbine from 60 to 80 mg/m day during induction (reasons for nonescalation: hematological 7 patients, nonhematological 2 patients, error 4 patients). After two cycles of chemotherapy induction, the OR intent-to-treat in the 54 patients was 37%. Toxicities during induction were as follows: Neutropenia G3-4 (28%), Febrile Neutropenia (7%), nausea G3 (11%), vomiting G3-4 (9%), anorexia G3 (4%), diarrhea G4 (2%), constipation G3 (2%). Forty-seven out of 54 (87%) patients received concomitant chemo-radiotherapy.Median radiotherapy delivered dose was 66 Gy. Tolerance: 9% G3 Neutropenia; 4% G3 dysphagia/radiation; 2% G3 radiation dermatitis. Late pulmonary fibrosis was reported in one patient (1.8%). One month after completion of chemo-radiotherapy, the overall OR intent-to-treat in the 54 patients was 54% (95% CI: 40-67%). With a median follow-up of 37 months (95% CI: 34-41) the median progression-free survival and overall survival were: 12.5 (95% CI: 9.6-16.4) and 23.4 (95% CI: 17.6-29.8) months, respectively.
  
  
  CONCLUSIONS
  Oral vinorelbine in combination with cisplatin is an effective combination in stage IIIA/IIIB patients. The excellent tolerance profile allowed to complete concomitant chemo-radiotherapy in 87% of patients. Oral vinorelbine in combination with cisplatin is a new and promising option that facilitates the administration of concomitant chemo-radiotherapy with high rates of treatment completion.
authors.affiliation: Institut de Recherche Pierre Fabre, Boulogne Billancourt, France.
authors.forename: Maciej
authors.initials: M
authors.lastname: Krzakowski
authors.forename: Mariano
authors.initials: M
authors.lastname: Provencio
authors.forename: Beata
authors.initials: B
authors.lastname: Utracka-Hutka
authors.forename: Eugenio
authors.initials: E
authors.lastname: Villa
authors.forename: Manuel
authors.initials: M
authors.lastname: Codes
authors.forename: Abraham
authors.initials: A
authors.lastname: Kuten
authors.forename: Michael
authors.initials: M
authors.lastname: Henke
authors.forename: Massimo
authors.initials: M
authors.lastname: Lopez
authors.forename: David
authors.initials: D
authors.lastname: Bell
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Biti
authors.forename: Ofer
authors.initials: O
authors.lastname: Merimsky
authors.forename: Aulo
authors.initials: A
authors.lastname: Beorchia
authors.forename: Marcello
authors.initials: M
authors.lastname: Riggi
authors.forename: Noël-Raphaël
authors.initials: NR
authors.lastname: Caux
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Pouget
authors.forename: Bernard
authors.initials: B
authors.lastname: Dubray
authors.forename: Philippe
authors.initials: P
authors.lastname: David